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Abstract
Despite the emerging success of multi-targeted protein tyrosine kinase (PTK) inhibitors in cancer therapy, significant side
effects and resistance concerns seems to be avoided unlikely. The aim of the present study was to identify novel multi-
targeting PTK inhibitors. The kinase enzymatic activities were measured by enzyme-linked immunosorbent assay (ELISA).
The antiproliferative activities in human microvascular endothelial cells (HMECs) were evaluated by sulforhodamine (SRB)
assay. The phosphorylation of kinases and their downstream molecules was probed by western blot analysis. The binding
mode between MdOS and PTKs was profiled by surface plasmon resonance (SPR) approach and molecular simulation. Tube
formation assay, rat aortic ring method and chicken chorioallantoic membrane assay were combined to illustrate the in vitro
and in vivo anti-angiogenic effects. Results indicated that MdOS, a novel marine-derived oligosaccharide sulfate, exhibited a
broad-spectrum PTK inhibitory action. At an enzymatic level, MdOS inhibited HER2, EGFR, VEGFR, PDGFR, c-Kit, FGFR1 and c-
Src, with little impact on FGFR2. In cellular settings, MdOS inhibited phosphorylation of PTKs, exemplified by HER2, EGFR
and VEGFR2, and downstream molecules of Erk1/2 and AKT. Further studies demonstrated that MdOS acted as an ATP-
competitive inhibitor via directly binding to the residues of entrance rather than those of the ATP-binding pocket.
Furthermore, MdOS inhibited proliferation and tube formation of HMECs, arrested microvessel outgrowth of rat aortic rings
and hindered the neovascularization of chick allantoic membrane. Taken together, results presented here indicated that
MdOS exhibited anti-angiogenic activity in a PTK-dependent manner and make it a promising agent for further evaluation in
PTK-associated cancer therapy.
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Introduction
Protein tyrosine kinases (PTKs) play crucial roles in signal
transduction pathways that regulate a number of cellular
functions, such as cell proliferation, differentiation, migration
and apoptosis[1,2,3]. Deregulated expression of PTKs is respon-
sible for tumor development and progression, including hyper-
proliferation, angiogenesis, invasion and chemotherapy resistance,
and have been validated clinically as promising new targets in
cancer therapy [2,4,5].
Over the past years, there has been a proliferation of agents
designed to inhibit single PTK in tumor, including those directed
against Bcr-Abl (e.g. imatinib mesylate)[6], epidermal growth
factor receptor (EGFR, e.g. erlotinib)[7], HER-2/neu (e.g.
trastuzumab)[8]. However, with the exception of a few malignan-
cies that seem to be driven by a single genetic mutation in a gene
encoding a signaling protein, most tumors are triggered by
multiple mutations in multiple aberrant signaling pathways[9].
Thus, antitumor efficacy of single molecular-targeted agents might
be limited. As such, there has been an intriguing interest in
discovering and developing novel multi-targeted PTK inhibitors,
and most of them focused on small molecular entities. In point of
fact, Sunitinib (Sutent, SU11248) and Sorafinib (Nexavar, BAY43-
9006), two multi-targeted PTK inhibitors, have shown significant
clinical benefits in cancer therapy and approved for the treatment
of advanced renal cell carcinoma (RCC) [10,11,12,13].
Since small molecule inhibitors may not only possess potent
cytotoxicity and poor solubility, they may also increase the
likelihood of development of resistance [14,15,16], an exciting
challenge of current strategies is to develop new multi-targeting
PTK inhibitors with novel scaffolds. To this end, inhibitors are
expected to involve those distinct structures from the conventional
small molecules.
The oligosaccharides bear unique backbone totally different
from that of small molecules that have never been challenged in
this setting. Enzyme-linked immunosorbent assay (ELISA), a
sensitive and specific assay for the detection and quantification of
antigens or antibodies, has been widely used in tyrosine kinase
related drug discovery research due to easy-handling and free from
radio-contamination, in particular comparing to 32P incorpora-
PLoS ONE | www.plosone.org 1 November 2008 | Volume 3 | Issue 11 | e3774tion [17,18,19]. In this paper, with the availability of the newly
established in vitro ELISA-based PTK enzymatic profiling assays
in our laboratory and in particular, with the marine-derived
carbohydrate library in hand, we are encouraged to touch the kind
of this class for seeking novel PTK inhibitors. MdOS, a newly
semi-synthesized, structurally novel oligosaccharide derived from
marine oligomannurarate blocks (Fig. 1), stood out as a potent
multi-targeted PTK inhibitor by inhibiting HER2, EGFR,
VEGFR2, PDGFR, c-Kit and c-Src. Further studies demonstrate
that MdOS exerted anti-angiogenic activities both in vitro and in
vivo. All these promise MdOS in particular and, oligosaccharide
possible in general, to be a new and hitherto unrecognized scaffold
as multi-targeted PTK inhibitors in cancer therapy.
Results
MdOS broadly inhibits enzymatic activities of a panel of
purified tyrosine protein kinases
The effects of MdOS on the activities of various tyrosine kinases
were evaluated using enzyme-linked immunosorbent assays (ELISAs)
with purified recombinant proteins. As shown in Table 1, MdOS
potently inhibited the kinase activities of HER-2, EGFR and
VEGFR2 with IC50 values of 0.13, 0.28 and 1.8 mg/ml, respectively.
Moreover, MdOS moderately inhibited those of PDGFRb,c - K i t ,c -
Src and FGFR1, but had little effect on that of FGFR2. MdOS is,
therefore, a multi-targeted tyrosine kinase inhibitor.
Given the relative high inhibitory potency of MdOS against
HER-2, EGFR and VEGFR2, together with the fact that HER-2,
EGFR and VEGFR2 are the most verified targets in cancer
therapy, we took these three kinases as representatives to probe
MdOS -driven PTKs-associated events.
MdOS blocks tyrosine kinase phosphorylation and
downstream signaling in cells
We next intended to investigate the kinase inhibitory activity of
MdOS at cellular level. For this, both naturally and genetically
kinase expressing cell lines were selected.
MdOS inhibits EGF-induced HER-2 phosphorylation and
downstream signaling. The activity of MdOS against HER-2
was followed by measuring receptor autophosphorylation in
naturally HER-2-overexpressing SK-OV-3 cells and a newly
generated NIH-3T3 cells lines stably expressing HER-2 (NIH-
3T3/neu cells). MdOS dose-dependently dephosphorylated HER-
2, with a complete abolishment obtained at 100 mg/ml (Fig. 2A).
Erk1/2 and AKT, the key downstream molecules of HER-2,
playing important roles in cell proliferation and survival, were also
significantly dephosphorylated upon MdOS treatment (Fig. 2A).
Likewise, MdOS produced a similar pharmacological profile in
NIH-3T3/neu cells, with its inhibitory effect observed even at a
concentration of 2 mg/ml (Fig. 2B).
MdOS inhibits EGF-induced EGFR phosphorylation and
downstream signaling. The effects of MdOS on EGFR were
measured in naturally EGFR-overexpressing A431 and MDA-MB-
468 cells. As shown in Figure 2C, MdOS caused a concentration-
dependent abrogation of phosphorylation of EGFR in A431 cells,
which was accompanied by a complete abolishment of AKT
phosphorylation (10 mg/ml). In contrast, MdOS caused a slight
decrease in Erk1/2 phosphorylation (even at 100 mg/ml). In MDA-
MB-468 cells, MdOS obviously inactivated EGFR at concentration
of 50 mg/ml, and dephosphorylated both Erk1/2 and AKT even at
10 mg/ml (Fig. 2D). All these results indicate that MdOS blocks
EGFR and its downstream signaling events.
MdOS inhibits VEGF-induced VEGFR2 phosphorylation
and signaling. We explored the kinase-inhibitory effects of
MdOS on VEGFR2 using HMEC cells that naturally overexpress
VEGFR2 and a newly generated NIH-3T3 cells lines stably
expressing VEGFR2 (NIH-3T3/flk1 cells). Interestingly, MdOS
was noted to be more effective against VEGFR2 in cellular assay
compared with the inhibitory potency against HER-2 and EGFR.
Figure 1. Structure of MdOS.
doi:10.1371/journal.pone.0003774.g001
Table 1. Effects of MdOS on the activity of a panel of tyrosine
kinases.
Kinase IC50 (mg/ml)
HER-2 0.1360.09
EGFR 0.2860.01
VEGFR2 1.860.6
VEGFR1 2.460.4
PDGFRb 1.860.3
c-Kit 462
c-Src 0.760.2
FGFR1 0.6860.08
FGFR2 .20
Kinases activity was assayed by ELISA. Concentrations that cause 50% inhibition
(IC50) are shown as mean6SD of three to six separate experiments performed in
duplicate. EGFR, epidermal growth factor receptor; VEGFR, vascular endothelial
growth factor receptor; PDGFR, platelet derived growth factor receptor; FGFR,
fibroblast growth factor receptor.
doi:10.1371/journal.pone.0003774.t001
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complete blockage of VEGFR2 phosphorylation, followed by an
obvious inhibition on Erk1/2 phosphorylation, but no effect on
AKT. MdOS (50 mg/ml) also caused a dramatic abrogation of
phosphorylation of VEGFR2 in NIH-3T3/flk-1 cells,
accompanied by a complete abolishment of Erk1/2
phosphorylation and an obvious inhibition on AKT
phosphorylation (Fig. 2F).
Taken together, MdOS can inhibit phosphorylation of HER-2,
EGFR and VEGFR2 intracellularly, with potency against
VEGFR2 relatively higher than the other two.
MdOS targets intracellular tyrosine kinase rather than
extracellular growth factors
Consensus view holds that oligosaccharides act extracellularly
by inhibiting the interactions of growth factors to their receptors.
Figure 2. Inhibition of MdOS on cellular kinase phosphorylation and signal transduction. A–B, MdOS blocks HER-2 phosphorylation and
its downstream signal transduction in SK-OV-3 cells (A) and NIH-3T3/neu cells (B). C–D, Inhibition of EGF-stimulated EGFR phosphorylation and signal
transduction by MdOS in A431 (C) and MDA-MB-468 (D) cells. Serum-starved cells were incubated with indicated concentrations of MdOS for 6 h at
37uC, EGF (50 ng/ml) was added to the cultures during the last 15-min treatment. E–F, Inhibition of VEGF-stimulated VEGFR2 phosphorylation and
signal transduction by MdOS. HMEC (E) and NIH-3T3/flk-1 (F) cells were starved, then incubated with indicated concentrations of MdOS for 6 h at
37uC, VEGF (50 ng/ml) was added to the cultures during the last 15-min treatment. Protein samples were separated by SDS-PAGE and probed using
the indicated antibodies. Representative data are shown.
doi:10.1371/journal.pone.0003774.g002
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distinctly identified to arrest the kinase activity of growth factor
receptors mainly via its intracellular action. To further confirm the
MdOS-driven intracellular events, we first examined the cell entry
of MdOS by using a FITC-labeled MdOS (FITC-MdOS, green)
probe in SK-OV-3 cells[20]. As shown in Figure 3A, high levels of
green fluorescence were detected in the MdOS-treated SK-OV-3
cells, while no visible green fluorescence was noted in untreated
cells. Green fluorescence reached saturated upon 30-min exposure
(data not shown), indicative of a rapid uptake of MdOS into cells.
The fluorescence co-localization analysis further revealed that
MdOS partially superimposed with HER-2 tyrosine kinase in SK-
OV-3 cells, favoring appreciable entry of MdOS into cells.
To provide more direct evidence and rule out contributions of
extracellular activity, we then carried out another subsequent
experiments, by withdrawing the added MdOS prior to the
exposure of growth factors and by depriving the growth factors
from the experimental settings as well. As expected, MdOS
inhibited the phosphorylation of HER-2 in SK-OV-3 cells in the
MdOS-withdrawal sample similar to that in MdOS-unwithdrawal
sample (Fig. 3B, left). Likewise, MdOS also blocked phosphory-
lated HER-2 in SK-OV-3 cells in growth factor-deprived settings
(Fig 3B, right).
Together with our previous data in Figure 2, our results
substantiate that MdOS directly inhibit cellular tyrosine kinase
activity independent of extracellular activity, and strongly support
that MdOS behaves distinctly from the conventional oligosaccha-
rides.
MdOS potently binds to the kinase domain of VEGFR2,
HER-2 and EGFR
Wenext determined whether the inhibitoryeffect of MdOS on the
activity of VEGFR2, HER-2 and EGFR is associated with the direct
engagement with tyrosine kinases. SPR assay was employed to assess
the interaction between MdOS and VEGFR2 or HER-2 or EGFR.
For this, MdOS was immobilized on CM-5 sensor chips. The
response of binding units of MdOS to VEGFR2 or HER-2 or EGFR
was recorded. MdOS was noted to display a high-binding affinity for
VEGFR2, yielding the equilibrium dissociation constant (KD)o f
5.76610
27 M (Fig. 4A). Similar results were observed in MdOS-
HER-2 (Fig. 4B) and MdOS-EGFR binding settings (Fig. 4C), with
KD values of 5.47610
27 M and 6.27610
26 M, respectively.
To address whether the histine tagged on the proteins interacts
with MdOS or not, binding between MdOS and 66his-tag was
examined. As shown in Figure 4D, no obvious association was
found between MdOS and pure 66his-tag. These results
Figure 3. MdOS directly targets intracellular tyrosine kinase. A, Cell entry and location of MdOS. SK-OV-3 cells were treated as described in
the materials and methods, and photographed by Leica TCS confocal microscope. Bar, 10 mm. B, Left, starved SK-OV-3 cells were incubated with
100 mg/ml MdOS for 6 h, followed by stimulated with EGF directly or washed three times with serum-free medium then stimulated with EGF (+w).
Right, SK-OV-3 cells were plated in six-well plates. 24 h after plating, medium was replaced with serum-free medium supplemented with indicated
concentrations of MdOS for 6 h.
doi:10.1371/journal.pone.0003774.g003
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ability of our protein to MdOS, permitting the identity of His-
tagged proteins to the native ones in terms of the biological
outcomes of their interactions with MdOS.
MdOS functions as an ATP competitive inhibitor of
VEGFR2, HER-2 and EGFR
Most small molecular inhibitors are designed to block kinase
activity via binding to the ATP pocket of the enzyme. To examine
whether MdOS also acts as an ATP competitive inhibitor, we
evaluated the inhibitory potency of MdOS on kinase enzymatic
activities using competitive inhibitory assay by introduction of
different concentrations of ATP. As shown in Figure 5, Line-
weaver-Burke plots for inhibition of VEGFR2, HER-2 and EGFR
tyrosine kinases by MdOS with respect to ATP concentration
showed all curves intersecting the y-intercept at zero, which is
indicative of a competitive mechanism of inhibition.
MdOS binds to the entrance of ATP binding pocket of
VEGFR2 and EGFR
In order to go further insights into interaction mode of MdOS
with these kinase proteins at the atomic level, the automated
docking simulation exemplified by MdOS-VEGFR2 and MdOS-
EGFR interaction were performed. The crystal structures of
human VEGFR2 and EGFR kinases were utilized as the target
structures, with the disaccharide of MdOS as docking probe. In
the model of VEGFR2, it was remarkably noted that different
from the classic small molecule inhibitors that probed deeply into
the ATP binding pocket, MdOS was docked at the entrance of the
ATP-binding pocket of VEGFR2 (Fig. 6A). In a zoomed-in view,
two sulfate moieties of MdOS are hydrogen-bonded to the
sidechain carbonyl oxygen of Glu883 and Asp1044 respectively,
and the carboxyl group of MdOS generates two hydrogen bonds
with the hydroxyl group of Ser882 (Fig. 6B). In addition, the sugar
moiety forms hydrophobic interactions with residues Phe843 and
Glu883.
Similar binding mode was observed in MdOS and EGFR
kinase. Likewise, MdOS also encompassed the entrance of the
ATP pocket of EGFR (Fig. 6C), with one sulfate moiety hydrogen
bonding to Cys773 (Fig. 6D). And the sugar moiety forms
hydrophobic interactions with residues Asp776. All these allow
MdOS to mask entrance of ATP-binding pocket, thereby blocking
the engagement of ATP with VEGFR2 and EGFR, which further
help understand the ATP-competitive inhibitory competence of
MdOS.
Figure 4. Interaction of VEGFR-2 (A) or HER-2 (B) or EGFR (C) or 66his-tag (D) with MdOS by surface plasmon resonance analysis.
VEGFR2 was injected at the concentrations of 2.56, 0.64, 0.32, 0.16 and 0.08 mM (from top to bottom); HER-2 was injected at the concentrations of
0.53, 0.26, 0.13, 0.07 and 0.03 mM (from top to bottom); EGFR was injected at the concentrations of 6, 3, 1.5, 0.75, 0.38, 0.19 and 0.09 mM (from top to
bottom); 66his-tag was injected at the concentrations of 100, 10, 1, 0.1, 0.01 mM. Sensorgram responses at equilibrium were plotted against each
concentration of compounds and the equilibrium dissociation constant (KD) of the binding system was calculated using BIAeval software 3.1.
doi:10.1371/journal.pone.0003774.g004
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PLoS ONE | www.plosone.org 5 November 2008 | Volume 3 | Issue 11 | e3774Figure 6. Predictive interaction between MdOS and VEGFR2 or EGFR by molecular docking. A, binding mode of MdOS and VEGFR2
kinase (PDB code: 1YWN). B, the detailed binding interactions between MdOS and VEGFR2 kinase. Hydrogen bonds are indicted by dashed lines. C,
binding mode of MdOS and EGFR kinase (PDB code: 1XKK). D, the detailed binding interactions between MdOS and EGFR kinase. Hydrogen bonds
are indicted by dashed lines.
doi:10.1371/journal.pone.0003774.g006
Figure 5. Lineweaver Burke plot of ATP competition. VEGFR2 (A) and HER-2 (B) and EGFR (C) kinase assays were performed as described in
Materials and Methods in the presence of varying concentrations of ATP. Initial reaction velocity was expressed as the phosphorylation of poly(Glu,
Tyr)4:1 substrate. All x, y data sets were multiplied by 100 for purposes of graphical presentation.
doi:10.1371/journal.pone.0003774.g005
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and in vivo
VEGF and VEGFR2 signaling in endothelial cells is primarily
responsible for tumor angiogenesis. MdOS preferably inhibited
the proliferation of HMECs (data not shown) and particularly
suppressed VEGFR2 phosphylation and subsequent downstream
signaling in HMECs (Fig. 2E). In addition, MdOS also targeted
HER-2, EGFR, FGFR and PDGFR that are directly or indirectly
involved in tumor angiogenesis[21,22,23]. All these prompted us
to hypothesize that MdOS might exhibit anti-angiogenic effects.
To address this issue, we first defined the appropriate
concentrations and duration that is irrelevant to the cytotoxic
effect of MdOS. For this, both MTT and BrdU incorporation
assays were selected. MdOS demonstrated little inhibitory impact
on cell viability within 12 h, even at concentration of 100 mg/ml
(data not shown). Accordingly, the concentrations no more than
100 mg/ml and exposure time within 12- h were selected for the
subsequent experiments.
MdOS arrests growth factors-induced proliferation in
HMECs. VEGF, EGF, bFGF and PDGF have been clearly
identified as positive mediators of endothelial cell proliferation and
angiogenesis[24]. We examined the effects of MdOS on growth
factors-dependent HMEC cell proliferation. As expected, MdOS
displayed comparable inhibitory activities against VEGF-, EGF-,
bFGF- and PDGF-driven HMECs proliferation (IC50 values of
48.3 mg/ml, 61.0 mg/ml, 56.2 mg/ml and 62.7 mg/ml,
respectively), whereas with less potency against FBS-mediated
events (IC50 value .200 mg/ml) (Fig. 7A). These findings further
substantiate the multi-targeted profiles of MdOS in HMECs and
the likely potential of its anti-angiogenic efficacy.
MdOS disrupts HMEC tube formation on matrigel. As
tube formation represents one of the late stage of angiogenesis, we
next evaluated the effects of MdOS on tube formation of HMECs
on a Matrigel substratum[25]. In the control group, HMECs
formed a mesh of tubes within 8 h. The tube structures were
severely and concentration-dependently disrupted when cells were
exposed to MdOS. Notably, HMECs treated with lower
concentrations (10 and 50 mg/ml) of MdOS differentiated into
short tubes but were unable to form meshes, whereas those treated
with higher concentration of MdOS (100 mg/ml) remained dotted
on the Matrigel (Fig. 7B).
MdOS inhibits microvessel outgrowth from rat aortic
rings. We further evaluated the anti-angiogenic effects of
MdOS in an ex vivo aorta sprout outgrowth assay [25]. We
found that new microvessels began to grow when control cultures
were incubated for 6 days. Treatment with MdOS (50, 100 and
200 mg/ml) resulted in a notable suppression of microvessel
formation versus the control (Fig. 7C).
MdOS abrogates neovascularization in a CAM
model. To determine whether anti-angiogenic effects of
MdOS could be recapitulated in vivo, we extended our studies to
a CAM model [25]. As shown in Figure 7D, the normal branching
pattern of blood vessels formed over a 2 day incubation in the
control group, whereas MdOS at 200 mg/egg completely blocked
this angiogenesis.
Discussion
The high frequency of genetic alterations in cancer cells
resulting in permanent activation of protein tyrosine kinases has
led to the positioning of these kinases as therapeutic targets[26]. It
is believed that there is multi-level cross-stimulation among targets
along several pathways of signal transduction that lead to
malignancy in tumor. Blockage on one pathway, as most single-
target agents do, other pathways are compensatorily allowed to act
as salvage or escape mechanisms [27]. As such, a multi-targeted
approach where several pathways are selectively and simulta-
neously suppressed at the RTK level represents an attractive
Figure 7. The inhibitory action of MdOS on angiogenesis. A,
effect of MdOS on growth factor-stimulated proliferation of human
microvascular endothelial cells (HMECs). HMECs proliferation was
assayed as described in Materials and Methods. B, effect of MdOS
against HMEC tube formation on Matrigel. HMECs were plated on
Matrigel in medium with various concentrations of MdOS for 8 h. Left,
representative photographs (1006) of three independent experiments.
Right, quantification of the inhibitory activity of MdOS on tube
formation. C, effect of MdOS on microvessel outgrowth arising from
rat aortic ring. Aortic rings were embedded in Matrigel in 96-well plates,
then fed with medium containing various concentrations of MdOS for 6
days. Left, representative photographs (1006) of three independent
experiments. Right, the area of microvessels was quantified and
normalized to untreated controls. D, effect of MdOS on angiogenesis
in a chorioallantoic membrane model. Glasscover-slip saturated with
MdOS or normal saline was placed areas between preexisting vessels in
the fertilized chicken eggs and incubated for 48 h. Left, representative
photographs (1006) of three independent experiments. The Glass-
cover-slip was placed on the right side of the field. Right, the number of
vessel branches was quantified and normalized to untreated controls.
Data shown are mean6SD from three independent experiments.*,
P,0.05; **, P,0.01, versus control.
doi:10.1371/journal.pone.0003774.g007
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favors the overcome of resistance that commonly occurs in single-
targeting monotherapy[28]. Therefore, the multi-targeted ap-
proaches are anticipated through either combination of selectively
defined agents or by a single agent with multiple targets. The
latter, in this scenorio, offers the favorable advantages over the
combined therapy due to the multi-functional convenience, easier
dosing regimens, and potential lower costs.
With an increasing understanding of SAR-based efficacy versus
toxicity of multi-targeted PTK inhibitors, these benefits emerge to
weight against the potential limitation, for instance, the mutations
in residues of ATP-binding cleft disable the active access of the
established inhibitors to the ATP-binding domain, thereby offering
the inevitable resistance [29,30]. A logical approach, therefore,
would involve compounds that bind to residues beyond or far off
the ATP-binding cleft. Of note, the tyrosine kinase inhibitors are
more often the kind of small molecules that have been directed
towards this ATP-binding pocket. The therapeutic options are
considered with those agents of structurally novel skeletons.
MdOS is structurally defined as a 1,4-linked b-D-mannuronate
of pyranohexuronic acid residues with the reducing end oxidized
to mannurarate, bearing an average of 1.5 sulfates per sugar
residue at the 2-hydroxyl, partial 3-hydroxyl with partial
esterification at 6-carboxyl groups. This structure offers MdOS
appreciable negative charges, which allows MdOS to afford a
high-affinity interaction with PTK in a broad spectrum manner.
Our ELISA-based kinase inhibitory outcomes that MdOS broadly
inhibited PTKs, together with our cellular assays that MdOS
inhibited PTKs phosphorylation and downstream signaling,
substantiate this story. The concomitant in vivo anti-angiogenic
efficacies of MdOS should be the synergistic outcomes of this
broad-spectrum inhibitory action. Notably, the unique binding
mode by the simulation exercise that MdOS hydrogen bonded to
the residues of the entrance rather than those of ATP-binding
pocket helps, from a theoretical view, to understand the likely
distinct pharmacological profiles from small molecules in general
and, the potential value against small molecule-evoked resistance
in particular. Of course, much hope lies on further investigation.
Although electrostatic charges are viewed to initiate attach-
ments between sugars and proteins, the structure-based confor-
mation likely dominates the functions. The alternative findings
that some other marine-derived oligosaccharides, even bearing the
same negative charges but with different sugar compositions, did
not generate the likelihood of functions as MdOS did (data not
shown), help reinforce this view. The structural components
responsible for interactions between PTK and sulfated oligosac-
charides have not been well characterized, but the nature of the
sugar scaffold seems to be critical, and distribution of sulfation
seems essential.
In summary, this is the first time to disclose that MdOS, a
marine-derived oligosaccharide, functions as a broad spectrum of
tyrosine kinase inhibitor. It is canonically viewed that oligosac-
charides act extracellularly by inhibiting the interactions of growth
factors to their receptors [31]. However, distinctly from this
commonly accepted concept, MdOS represents an alternate
mechanism via arresting intracellularly the kinase activity of
growth factor receptors. As yet, it cannot exclude the partial
extracellular activity of MdOS on angiogenesis, but we focus on
the intracellular function of MdOS in this study. The appreciable
pharmacological profiles, the distinct action of mode as well as the
low cytotoxic settings (data not shown) underscore the importance
of MdOS as a new lead scaffold in anti-cancer drug development.
With research continuing to dig the insights into the structure-
based machinery of this kind of oligosaccharide, it is hoped that
the future will add impetus to the search for carbohydrate-based
multi-targeted PTK inhibitors in cancer therapy.
Materials and Methods
Compound
The oligomannuronic acid was degraded by hydrogen peroxide
from polymannuronate blocks obtained from sodium alginate.
The MdOS compound was further obtained by semi-synthesis
following sulfate modification by reacting its precursor with
ClSO3H in formamide after partially esterified at the 6-carboxyl
groups. Briefly, oligomannuronate was mixed with propylene
oxide at a certain ration, and the reaction was catalyzed by NaOH
at 45uC for 3 h. Then the esterified products were added to
sulfating reagents containing formamide and ClSO3H, and
reacted for 3 h. The pH of the products was adjusted to 7.0 with
NaOH, and desalted using Sephadex G-10. The product peak was
pooled and freeze-dried. The molecular weights of MdOS and its
precursor were analyzed by High Performance Gel Permeation
Chromatography (HPGPC) using a TSK G3000PWxl column
(300 mm67.8 mm) (Tosoh, Tokyo, Japan). Stock solutions were
prepared in saline solution at 10 mg/ml and then diluted to the
desired concentration with saline solution.
Cells and cell culture
Human squamous cancer cells A431, human ovarian cancer
cells SK-OV-3, human micro-vascular endothelial cells (HMECs)
and mouse fibroblast cells NIH-3T3 were obtained from the
American Type Culture Collection (Rockville, MD). NIH-3T3/
neu and NIH-3T3/flk-1 were established as described previous-
ly[32]. SK-OV-3 and NIH-3T3 cells were maintained in high-
glucose DMEM (Gibco, Grand Island, NY) with 10% FBS,
100 IU/ml benzylpenicillin, and 100 mg/L streptomycin. A431
cells were maintained in DMEM with 10% FBS, 4 mM L-
glutamine, 100 IU/ml benzylpenicillin, and 100 mg/L strepto-
mycin. HMECs were grown in MCDB-131 medium containing
10% FBS. NIH-3T3/neu and NIH-3T3/flk-1 cells were main-
tained in DMEM (Gibco, Grand Island, NY) with 10% FBS,
100 IU/ml benzylpenicillin, 100 mg/L streptomycin and
600 mg/L G418. All cells were cultured in humidified atmosphere
of 95% air and 5% CO2 at 37uC.
Animals
Sprague-Dawley rats (6-week-old) were provided by Shanghai
Laboratory Animal Center, Chinese Academy of Sciences. The
use of animals was approved by the Institute animal reviews
boards of Shanghai Institute of Materia Medica, Chinese
Academy of Sciences, with confirm adherence to the ethical
guidelines for the care and use of animals.
ELISA kinase assay
The kinase domain of EGFR, HER-2, VEGFR2, c-Kit,
FGFR1, FGFR2 and c-Src were expressed using the Bac-to-
Bac
TM baculovirus expression system (Invitrogen, Carlsbad, CA,
USA) and purified on Ni-NTA columns (QIAGEN Inc., Valencia,
CA, USA) as previously described[33]. Recombinant PDGFRb
and VEGFR1 proteins were obtained from Upstate Biotechnology
(Lake Placid, NY. #14-463 and #14-562, respectively). The
tyrosine kinase activities of the purified EGFR, HER-2, Flt-1,
VEGFR2, PDGFRb, c-Kit, FGFR1, FGFR2 and c-Src kinase
domains were determined using ELISA methodology described
previously[34]. Briefly, 50 ml1 0 mM ATP solution diluted in
kinase reaction buffer (50 mM HEPES pH 7.4, 20 mM MgCl2,
0.1 mM MnCl2, 0.2 mM Na3VO4, 1 mM DTT) was added to
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buffered saline were added to each reaction well. 10 ml buffered
saline was used as the vehicle control. The kinase reaction was
performed in triplicate and initiated by adding purified tyrosine
kinase proteins diluted in 40 ml of kinase reaction buffer. After
incubation for 60 min at 37uC, the plate was washed three times
with Phosphate Buffered Saline (PBS) containing 0.1% Tween 20
(T-PBS). Next, 100 ml anti-phosphotyrosine (PY99) antibody
(1:500, Santa Cruz Biotechnology, Santa Cruz, CA) diluted in
T-PBS containing 5 mg/ml BSA was added and the plate was
placed at at 37uC for 30 min. After the plate was washed three
times, 100 ml Horseradish peroxidase-conjugated goat anti-mouse
IgG (1:2000, Calbiochem, San Diego, CA) diluted in T-PBS
containing 5 mg/ml BSA was added and the plate was
reincubated at 37uC for 30 min. The plate was washed, then
100 ml citrate buffer (0.1 M, pH 5.5) containing 0.03% H2O2 and
2 mg/ml o-phenylenediamine was added and samples were
incubated at room temperature until color emerged. The reaction
was terminated by adding 50 mlo f2MH 2SO4, and the plate was
read using a multiwell spectrophotometer (VERSAmax
TM,
Molecular Devices, Sunnyvale, CA,USA) at 492 nm. The
inhibition rate (%) was calculated with the formula: [1-(A492/
A492 control)]6100%. IC50 values were calculated from the
inhibitory curves. For ATP competitive assay, conditions were the
same as above except that varying concentrations of ATP were
added in the absence or presence of a single concentration of
MdOS to generate ATP concentration curves.
Western blot analysis
Cells were grown to half confluence in six-well plates, starved in
serum-free medium for 24 h, and then exposed to MdOS at
concentrations of 2, 10, 50 and 100 mg/ml for 6 h. For analysis of
receptor tyrosine kinase phosphorylation and downstream signal
transduction pathways, cells were stimulated with 50 ng/ml EGF
or VEGF (R&D Systems, Minneapolis, MN, USA) for 15 min at
37uC at the end of MdOS treatment. Western blot analyses were
subsequently performed as previous described[33], with the
antibodies against phospho-EGFR (Tyr1068) (#2234), phospho-
HER-2 (Tyr1248) (#2247), phospho-VEGFR2 (Tyr996) (#2474),
VEGFR2 (#2472), phospho-ERK1/2 (#9101), ERK1/2
(#9102), phosphor-AKT (Ser473) (#9271) and AKT (#9272)
(Cell Signaling Technology, Beverly, MA, USA), EGFR (sc-03),
HER-2(sc-284) and actin (sc-8432) (Santa Cruz Biotechnology,
Santa Cruz, CA).
Preparation of the fluorescence-tagged MdOS
MdOS was labeled with fluorescein isothiocyanate (FITC) as
previously described[20,35] (Chemical Journal of Chinese Uni-
versities 2002; 23(9):1704–08). Briefly, 400 mg MdOS was
dissolved in PBS (pH 8.0) followed by mixing with 400 mg
tyramine and 150 mg NaH3BCN. The mixture was stired at 37uC
for 96 h. The solution was then loaded on a Sephadex G25
column to isolate MdOS-Tyr. Then 200 mg MdOS-Tyr and
25 mg FITC (Sigma-Aldrich) were dissolved in 0.5 M NaHCO3
(pH 8.5), and reacted at room temperature overnight. The
solution was then loaded on a Sephadex G25 column to isolate
FITC-labeled MdOS (FITC-MdOS) from unreacted FITC. The
structure of the compound synthesized was confirmed by UV-VIS
spectra and 1H-NMR.
Immunofluorescence assay
For fluorescence staining, SK-OV-3 cells were plated on glass
culture slides at a density of 1610
5 cells/ml in DMEM medium
containing 10% FCS. The medium was replaced with serum-free
DMEM containing 100 mg/ml FITC-MdOS (green) or normal
saline for 6 h. Fixed preparations were obtained by exposing cells
on culture slides to 4% paraformaldehyde in PBS for 10 min at
25uC, followed by washing three times with PBS containing 0.2%
Triton X-100 for 5 min. For HER-2 proteins staining, cells were
blocked with 5% bovine serum albumin for 30 min, then
incubated with HER-2 antibody in 3% BSA (1:200) for 30 min,
and followed by coincubation with Alexa 633-conjugated
secondary antibody diluted in 3% BSA (1: 500) for 30 min. Then
1 mg/ml DAPI was added for visualization of nuclear acid.
coverslips were slightly dried for a few minutes and mounted on
the slides with anti-fade agent, and pictures were obtained using
Leica TCS confocal microscope (Leica, Deerfield, IL, USA).
Surface Plasmon Resonance Analysis
The kinetics and specificity of the binding reactions between
MdOS and VEGFR2 or HER-2 or EGFR or 66his-tag were
carried out with the BIAcore6surface plasmon resonance
apparatus. Briefly, MdOS was immobilized on CM5 sensor chips
according to the Ligand Thiol protocol described in the
application Handbook. To assess real-time binding capacity,
35 ml of soluble VEGFR2 or HER-2 or EGFR or 66his-tag was
injected over the sensor chip surface with the immobilized MdOS,
followed by washed with HBS-EP buffer for 5 min. The sensor
chip surface was regenerated using 60 ml NaCl (2 M). All binding
experiments were performed at 25uC with a constant flow rate of
10 ml/min HBS-EP. For binding affinity assessment, the associ-
ation phase was allowed to proceed to equilibrium. To correct for
nonspecific binding and bulk refractive index change, a blank
channel (FC2) without oligosaccharide was employed as a control
for each experiment. Sensorgrams for all binding interactions were
recorded in real time and analyzed after subtracting that from the
blank channel. Changes in mass due to the binding response were
recorded as resonance units (Ru). Binding kinetics and affinities
were determined by SPR using BIACORE software 3.1.
Molecular modeling
The crystal structure of VEGFR2 kinase in complex with a
known inhibitor was retrieved from the Brookhaven Protein Data
Bank (PDB entry 1YWN). The crystal structure of EGFR kinase in
complex with lapatinib was retrieved from the Brookhaven Protein
Data Bank (PDB entry 1XKK). The molecular geometry of MdOS
disaccharide was modeled using the ISIS draw 2.5 program
(Available from http://www.mdl.com). The initial structures were
minimized using molecular mechanics with the Tripos force field
[36] with Gasteiger–Marsilli charges[37], and the energy conver-
gence gradient value was set to 0.005 kcal/(mol A ˚). Docking studies
using the DOCK 4.0 program (Kuntz group, San Francisco, CA,
USA) [38]were performed to predict the binding of MdOS to
VEGFR2 or EGFR. Kollman-all-atom charges and Geisterger-
Hu ¨ckel charges were assigned to proteins and the MdOS,
respectively. Spheres were generated by the AutoMS and sphgen
programs encoded in DOCK4.0 to describe the shape of the
binding site. The hydrophobic and electrostatic properties of the
binding site were calculated by the program Grid4. And the
conformational flexibility of MdOS was considered during the
docking calculation. Finally, the evaluation with the lowest binding
energy was used to analyze ligand pose and the interaction model of
MdOS/VEGFR2 or MdOS/EGFR was produced using the
LIGPLOT program based on the docked complex structure[39].
Growth factor-induced cell proliferation assays
HMEC Cells were seeded in 96-well tissue culture plates. On
the next day, cells were incubated in serum-free medium with 1%
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MdOS and growth factors (50 ng/ml VEGF, EGF, bFGF,
PDGFBB or 10% FBS) were added. Cells were further cultured
for 2 days. Cell proliferation was determined using sulforhodamine
B (SRB; Sigma, St. Louis, MO, USA) assay.
Tube formation assay
96-well plates were coated with 60 ml liquid Matrigel (Eecton
Dickinson, Bedford, MA, USA) per well and incubated at 37uC for
1 h to promote gelling. HMECs (1.5610
4/well) were seeded on
the Matrigel and cultured in MCDB-131 with various concentra-
tions of MdOS for 8 h at 37uC and 5% CO2. Images were
recorded by an inverted phase contrast microscope (Olypus, IX70,
Japan), the enclosed networks of complete tubes from five
randomly chosen fields were counted and photographed.
Rat Aortic Ring Assay
The aortas were harvested from 6-week-old Sprague-Dawley
rats. Each aorta was cut into 1-mm slices and embedded in 70 ml
Matrigel in 96-well plates. The aortic rings were then fed with
100 ml of M199 with different concentrations of MdOS or vehicle
alone, and photographed on day 6. The quantity of microvessels is
valued by relative area covered with microvessels using Image-Pro
Express.
Chicken Chorioallantoic Membrane Assay
Groups of 10 fertilized chicken eggs were incubated in a
humidified egg incubator (Lyon, Chula Vista, CA) maintained at
37uC and 50% humidity and allowed to grow for 7 days. Gentle
suction was applied at the hole located at the broad end of the egg
to create a false air sac directly over the chicken chorioallantoic
membrane, and a 1-cm
2 window was removed from the egg shell
immediately. Glass coverslips (0.560.5 cm) saturated with com-
pounds or normal saline was placed on areas between preexisting
vessels and the embryos were further incubated for 48 h. The
neovascular zones beside the glass coverslips were photographed
under a stereomicroscope (Leica, MS5, Heerbrugg, Switzerland)
and printed out as 567i n
2 prints. Vessel branches ,3 mm long in
five random 161i n
2 zones per pictures were counted and five eggs
were chosen from each group.
Statistical analysis
All data are represented as mean6SD. The significance of
differences was assessed by Student’s t test. P-values of ,0.05 were
regarded as statistically significant.
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